keyword
MENU ▼
Read by QxMD icon Read
search

PFS

keyword
https://www.readbyqxmd.com/read/28727865/proton-beam-radiotherapy-and-concurrent-chemotherapy-for-unresectable-stage-iii-non-small-cell-lung-cancer-final-results-of-a-phase-2-study
#1
Joe Y Chang, Vivek Verma, Ming Li, Wencheng Zhang, Ritsuko Komaki, Charles Lu, Pamela K Allen, Zhongxing Liao, James Welsh, Steven H Lin, Daniel Gomez, Melenda Jeter, Michael O'Reilly, Ronald X Zhu, Xiaodong Zhang, Heng Li, Radhe Mohan, John V Heymach, Ara A Vaporciyan, Stephen Hahn, James D Cox
Importance: Proton beam radiotherapy (PBT) has the potential to reduce toxic effects in the definitive management of locally advanced non-small-cell lung cancer (NSCLC), but long-term prospective data are lacking. Objective: To report the final (5-year) results of a prospective study evaluating concurrent chemotherapy and high-dose PBT to treat unresectable stage III NSCLC. Design, Setting, and Participants: In this open-label, single-group assignment study, with median follow-up of 27...
July 20, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28727815/polymorphisms-associated-with-everolimus-pharmacokinetics-toxicity-and-survival-in-metastatic-breast-cancer
#2
Tomas Pascual, María Apellániz-Ruiz, Cristina Pernaut, Cecilia Cueto-Felgueroso, Pablo Villalba, Carlos Álvarez, Luis Manso, Lucia Inglada-Pérez, Mercedes Robledo, Cristina Rodríguez-Antona, Eva Ciruelos
PURPOSE: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability in toxicity and response to exemestane-everolimus treatment. The objective of this study was to perform an exploratory study analyzing the implication of single nucleotide polymorphisms (SNPs) on outcomes from this treatment through a pharmacogenetic analysis...
2017: PloS One
https://www.readbyqxmd.com/read/28727128/transvaginal-six-arm-mesh-opur-in-women-with-apical-pelvic-organ-prolapse-analysis-of-short-term-results-pelvic-floor-ultrasound-evaluation
#3
Tomasz Kluz, Edyta Wlaźlak, Grzegorz Surkont
OBJECTIVES: Analysis of feasibility, efficacy and short-term results after six-arm transvaginal mesh OPUR implantation in women with apical prolapse. MATERIAL AND METHODS: The same surgeon operated all of 39 women using mesh OPUR. Preoperatively patients had a standardized interview and clinical examination. Intraoperative and postoperative complications were analyzed. Postoperative evaluation included standardized interview, clinical examination and standardized pelvic floor ultrasound performed with 2D transvaginal probe and 4D abdominal probe...
2017: Ginekologia Polska
https://www.readbyqxmd.com/read/28726172/combined-treatment-for-non-small-cell-lung-cancer-and-breast-cancer-patients-with-brain-metastases-with-whole-brain-radiotherapy-and-temozolomide-a-systematic-review-and-meta-analysis
#4
REVIEW
Jingru Tian, Yien Luo, Juanjuan Xiang, Jingqun Tang
Brain metastasis is the leading cause of death among advanced non-small cell lung cancer (NSCLC) and breast cancer patients. The standard treatment for brain metastases is radiotherapy. The combination of radiotherapy and chemotherapy has been tested. However, the management of brain metastases has yet to be successful. Here, we aimed to determine the efficacy and safety of whole brain radiotherapy (WBRT) alone or in combination with temozolomide (TMZ) in NSCLC and breast cancer patients with brain metastases...
July 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28725988/interim-18-f-fgd-pet-ct-may-not-predict-the-outcome-in-primary-central-nervous-system-lymphoma-patients-treated-with-sequential-treatment-with-methotrexate-and-cytarabine
#5
Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Jin-Sook Ryu, Jooryung Huh, Chan-Sik Park, Jong Hoon Kim, Sang Wook Lee, Cheolwon Suh
(18)F-fluoro-2-dexoy-D-glucose-positron emission tomography (PET)/computed tomography (CT) is a useful imaging technique for monitoring the treatment response in lymphoma cases. We investigated the value of interim brain PET/CT (I-PET/CT) for monitoring the response to intensive methotrexate-based chemotherapy in primary central nervous system lymphoma (PCNSL) patients with diffuse large B cell lymphoma (DLBCL). Of the 76 PCNSL patients treated with intensive methotrexate and cytarabine chemotherapy between September 2006 and December 2012, 66 patients with DLBCL were included in this study...
July 19, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28725278/asco-2016-update-colorectal-liver-metastases
#6
REVIEW
Klaus Kaczirek
This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM...
2017: Memo
https://www.readbyqxmd.com/read/28725243/outcomes-of-salvage-high-dose-rate-brachytherapy-with-or-without-external-beam-radiotherapy-for-isolated-vaginal-recurrence-of-endometrial-cancer
#7
Shuhei Sekii, Naoya Murakami, Tomoyasu Kato, Ken Harada, Mayuka Kitaguchi, Kana Takahashi, Koji Inaba, Hiroshi Igaki, Yoshinori Ito, Ryohei Sasaki, Jun Itami
PURPOSE: This study was designed to retrospectively analyze outcomes of high-dose-rate (HDR) brachytherapy, with or without external beam radiotherapy (EBRT), in patients with vaginal recurrence of endometrial carcinoma, and to identify factors prognostic of patient outcomes. MATERIAL AND METHODS: The medical records of all patients who underwent HDR brachytherapy for initial recurrence in the vagina of endometrial cancer after definitive surgery between 1992 and 2014 were retrospectively reviewed...
June 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28724419/real-life-clinical-practice-results-with-vinflunine-in-patients-with-relapsed-platinum-treated-metastatic-urothelial-carcinoma-an-italian-multicenter-study-movie-goirc-01-2014
#8
Rodolfo Passalacqua, Silvia Lazzarelli, Maddalena Donini, Rodolfo Montironi, Rosa Tambaro, Ugo De Giorgi, Sandro Pignata, Raffaella Palumbo, Giovanni Luca Ceresoli, Gianluca Del Conte, Giuseppe Tonini, Franco Morelli, Franco Nolè, Stefano Panni, Ermanno Rondini, Annalisa Guida, Paolo Andrea Zucali, Laura Doni, Elisa Iezzi, Caterina Caminiti
BACKGROUND: Vinflunine is the only chemotherapeutic agent shown to improve survival in platinum-refractory patients with metastatic transitional cell carcinoma of the urothelium (TCCU) in a phase III clinical trial, which led to product registration for this indication in Europe. The aim of this study was to assess the efficacy of vinflunine and to evaluate the prognostic significance of risk factors in a large, unselected cohort of patients with metastatic TCCU treated according to routine clinical practice...
July 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28724348/efficacy-and-safety-of-polymer-free-stent-versus-polymer-permanent-drug-eluting-stent-in-patients-with-acute-coronary-syndrome-a-meta-analysis-of-randomized-control-trials
#9
Kang Gao, Yiguang Sun, Ming Yang, Ling Han, Liwei Chen, Wenze Hu, Ping Chen, Xiaohong Li
BACKGROUND: The efficacy and safety of polymer-free stent (PFS) versus permanent polymer drug-eluting stent (PPDES) in patients undergoing percutaneous coronary intervention (PCI) remain controversial. Our meta-analysis was undertaken to evaluate and compare the efficacy and safety of PFS with those of PPDES in patients undergoing PCI. METHODS: We searched PubMed, Cochrane Library, EMBASE, and Clinical Trials.gov databases for randomized controlled trials (RCTs)...
July 19, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28724282/survival-nomograms-after-curative-neoadjuvant-chemotherapy-and-radical-surgery-for-stage-ib2-iiib-cervical-cancer
#10
Claudia Marchetti, Francesca De Felice, Anna Di Pinto, Alessia Romito, Angela Musella, Innocenza Palaia, Marco Monti, Vincenzo Tombolin, Ludovico Muzii, PierLuigi Benedetti Panici
Purpose: To develop nomograms for predicting the probability of overall survival (OS) and progression-free survival (PFS) in locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical surgery . Materials and Methods: Nomograms to predict the 5-year OS rates and the 2-year PFS rates were constructed. Calibration plots were constructed, and concordance indices were calculated. Evaluated variables were body mass index, age, tumor size, tumor histology, grading, lymphovascular space invasion, positive parametria and positive lymph-nodes...
July 19, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28723884/preoperative-anemia-as-a-simple-prognostic-factor-in-patients-with-urinary-bladder-cancer
#11
Cheng Chen, Linkun Hu, Xiangxiang Li, Jianquan Hou
BACKGROUND To evaluate the incidence of preoperative anemia and its prognostic role in patients with urinary bladder cancer (BC). MATERIAL AND METHODS A total of 317 patients diagnosed with BC were enrolled in this retrospective cohort study. Univariate and multivariate analysis was used to identify independent prognostic factors and Kaplan-Meier survival analysis was applied to examine the influence of anemia on survival. RESULTS 109 patients (34.4%) were anemic with a median preoperative hemoglobin of 114 g/L (interquartile range 104 to 122...
July 19, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28723808/continuous-use-of-metformin-can-improve-survival-in-type-2-diabetic-patients-with-ovarian-cancer-a-retrospective-study
#12
Shan-Bing Wang, Kai-Jian Lei, Jia-Pei Liu, Yu-Ming Jia
Evidence indicates that type 2 diabetes may stimulate the initiation and progression of several types of cancer. Metformin, a drug most commonly used to treat type 2 diabetes, may inhibit cancer cell growth and reduce the risk of cancer. However, evidence of the antitumor effects of metformin on ovarian cancer is still limited.In this study, we retrospectively examined the effects of metformin on ovarian cancer patients with diabetes at our institution.We identified 568 consecutive patients who were newly diagnosed with ovarian cancer and treated between January 2011 and March 2014...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28723793/prognostic-value-of-neutrophil-to-lymphocyte-ratio-for-nasopharyngeal-carcinoma-a-meta-analysis
#13
Jun Yin, Yuan Qin, Yu-Kun Luo, Mei Feng, Jin-Yi Lang
BACKGROUND: The prognostic value of the neutrophil-to-lymphocyte ratio (NLR) for nasopharyngeal carcinoma (NPC) remains controversial. This study was designed to provide a more accurate assessment of the prognostic value, based on a meta-analysis. METHODS: A comprehensive search for relevant studies published before June 2016 was performed using the PubMed, Cochrane Library, and Web of Science databases. The correlations of NLR with overall survival (OS) and progression-free survival (PFS) were evaluated for NPC...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28723663/a-network-meta-analysis-on-the-efficacy-of-targeted-agents-in-combination-with-chemotherapy-for-treatment-of-advanced-metastatic-triple-negative-breast-cancer
#14
Long Ge, Yan Tang, Qiu-Ning Zhang, Jin-Hui Tian, Xiao-Hu Wang, Dawid Pieper, Bei Pan, Lun Li, Juan Ling, Zhi-Tong Bing, Ke-Hu Yang
OBJECTIVE: Our network meta-analysis aimed to determine the assistant efficacy of targeted therapy in combined with chemotherapy for advanced/metastatic triple-negative breast cancer (TNBC). RESULTS: A total of 15 randomized controlled trials (RCTs), involving 2,410 patients, met our inclusion criteria. Eight targeted agents involving 11 treatment arms were included. The methodological quality of included RCTs was acceptable. The results of direct comparisons showed that progression-free survival (PFS) was significantly longer with bevacizumab+chemotherapy when compared to chemotherapy alone (hazard ratio [HR] = 0...
July 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28723635/meta-analysis-of-the-efficacy-of-treatments-for-newly-diagnosed-and-relapsed-refractory-multiple-myeloma-with-del-17p
#15
Jinghua Liu, Hui Yang, Xiaochan Liang, Yuxin Wang, Jian Hou, Yanqin Liu, Jigang Wang, Fan Zhou
We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p). Thirteen prospective studies that evaluated 3,187 MM patients, including 685with del(17p), were included in our meta-analysis. The incidence of del(17p) in NDMM and RRMM patients was similar (13% vs. 14%, respectively, P = 0.64, I2 = 94%). The overall response rate (ORR) to new agents was 40.5% and 67.1%, respectively, in RRMM patients with or without del(17p) (P = 0.1, I2 = 63.9%). NDMM patients with del(17p) treated with PAD (bortezomib, adriamycin, and dexamethasone) induction therapy followed by bortezomib maintenance therapy had higher progression-free survival (PFS) (25...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28723519/individual-patient-data-analysis-of-randomized-clinical-trials-impact-of-black-race-on-castration-resistant-prostate-cancer-outcomes
#16
Daniel E Spratt, Yu-Wei Chen, Brandon A Mahal, Joseph R Osborne, Shuang G Zhao, Todd M Morgan, Ganesh Palapattu, Felix Y Feng, Paul L Nguyen
BACKGROUND: Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. OBJECTIVE: To examine the impact of black race on progression-free survival (PFS) and overall survival (OS) among men with metastatic castration-resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). DESIGN, SETTING, AND PARTICIPANTS: A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723376/ureteral-involvement-is-associated-with-poor-prognosis-in-upper-urinary-tract-urothelial-carcinoma-patients-treated-by-nephroureterectomy-a-multicenter-database-study
#17
Yuma Waseda, Kazutaka Saito, Junichiro Ishioka, Yoh Matsuoka, Noboru Numao, Yasuhisa Fujii, Yasuyuki Sakai, Fumitaka Koga, Tetsuo Okuno, Chizuru Arisawa, Shigeyoshi Kamata, Katsuji Nagahama, Hitoshi Masuda, Junji Yonese, Yukio Kageyama, Akira Noro, Toshihiko Tsujii, Shinji Morimoto, Shuichi Gotoh, Kazunori Kihara
BACKGROUND: The prognostic significance of tumor location for patients with upper urinary tract urothelial carcinoma (UUT-UC) has been disputed. Several papers have reported that ureteral cancer is associated with worse prognosis. OBJECTIVE: To investigate the prognostic significance of the presence of ureteral tumors in UUT-UC patients who underwent radical nephroureterectomy (RNU). DESIGN, SETTING, AND PARTICIPANTS: In this multicenter retrospective study, 1068 eligible patients (median follow-up: 40 mo [interquartile range: 17-77 mo]) were divided into three groups based on tumor location: renal pelvic, ureteral, and both-regional (having both renal pelvic and ureteral tumors)...
August 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723233/treatment-patterns-and-clinical-outcomes-with-pazopanib-in-patients-with-advanced-soft-tissue-sarcomas-in-a-compassionate-use-setting-results-of-the-spire-study
#18
Hans Gelderblom, Ian R Judson, Charlotte Benson, Ofer Merimsky, Giovanni Grignani, Daniela Katz, Klaus W Freivogel, Dara Stein, Minesh Jobanputra, Arron Mungul, Stephanie C Manson, Roberta Sanfilippo
BACKGROUND: A named patient program (NPP) was designed to provide patients with advanced soft-tissue sarcoma (aSTS) access to pazopanib, a multitargeted tyrosine kinase inhibitor. The SPIRE study was a retrospective chart review of participating patients. PATIENTS AND METHODS: Eligibility criteria for the NPP and SPIRE mirrored those of the pivotal phase-III study, PALETTE, which compared pazopanib with placebo in patients ≥18 years with aSTS and whose disease had progressed during or following prior chemotherapy or were otherwise unsuitable for chemotherapy...
July 19, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28722680/prognostic-role-of-mir-17-92-family-in-human-cancers-evaluation-of-multiple-prognostic-outcomes
#19
REVIEW
Feifei Liu, Feng Zhang, Xiangyu Li, Qi Liu, Wei Liu, Peng Song, Ziying Qiu, Yu Dong, Hao Xiang
Recent evidence indicates that miR-17-92 family might be an essential prognostic biomarker for human cancers. However, results are still inconsistent. We therefore performed a meta-analysis to evaluate the predictive role of miR-17-92 family in human cancer prognosis. We searched literatures published before March 31th, 2017 inPubMed, Cochrane and Embase databases. Twenty six studies were included in our analyses. The overall hazard ratios (HRs) showed that high expression level of miR-17-92 family was a predictor of poor overall survival (OS): adjusted HRs = 1...
July 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28721065/optimizing-the-treatment-of-bevacizumab-as-first-line-therapy-for-human-epidermal-growth-factor-receptor-2-her2-negative-advanced-breast-cancer-an-updated-meta-analysis-of-published-randomized-trials
#20
Cunfu Li, Aizhai Xiang, Xianzhi Chen, Kai Yin, Jinsong Lu, Wenjin Yin
BACKGROUND: Manifold data have demonstrated that the addition of bevacizumab to chemotherapy improved progression-free survival (PFS), while few trials have revealed its significant overall survival (OS) benefit. Furthermore, it still remains suspended how to maximize the benefits of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We sought to conduct a meta-analysis to assess the benefits of bevacizumab with chemotherapy and to identify the ideal chemotherapy partner of bevacizumab in the first-line setting for HER2-negative advanced breast cancer patients...
2017: OncoTargets and Therapy
keyword
keyword
62483
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"